Similar Items: Predictors of Successful Secukinumab Dose Tapering in Moderate-to-Severe Psoriasis: A Retrospective Study
- Pingueculitis in psoriasis patient on secukinumab – An unreported adverse event
- Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study
- Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis
- Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis
- Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)
- Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP–GPP Overlap